Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amphastar Pharmaceuticals

29.83
-0.6700-2.20%
Post-market: 29.830.00000.00%16:20 EDT
Volume:374.38K
Turnover:11.17M
Market Cap:1.39B
PE:11.13
High:30.55
Open:30.53
Low:29.47
Close:30.50
52wk High:53.96
52wk Low:20.39
Shares:46.50M
Float Shares:35.34M
Volume Ratio:0.79
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.68
EPS(LYR):3.29
ROE:18.32%
ROA:7.31%
PB:1.83
PE(LYR):9.06

Loading ...

Stock Track | Amphastar Pharmaceuticals Soars 6.54% on Exclusive Licensing Deal and Analyst Upgrade

Stock Track
·
Aug 12

Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday

MT Newswires Live
·
Aug 12

Stock Track | Amphastar Pharmaceuticals Soars 5.63% Pre-market on Exclusive Licensing Deal and Analyst Upgrade

Stock Track
·
Aug 12

Needham Upgrades Amphastar Pharmaceuticals to Buy From Hold, Price Target is $36

MT Newswires Live
·
Aug 12

BRIEF-Amphastar Pharmaceuticals Enteres License Agreement With Nanjing Anji Biotechnology

Reuters
·
Aug 12

Amphastar Pharmaceuticals Inc : Needham Raises to Buy From Hold

THOMSON REUTERS
·
Aug 12

Amphastar Pharmaceuticals Inc - to Pay up to $267 Mln in Milestone Payments - SEC Filing

THOMSON REUTERS
·
Aug 12

Amphastar Pharmaceuticals Inc - on August 8, Entered License Agreement With Nanjing Anji Biotechnology - SEC Filing

THOMSON REUTERS
·
Aug 12

Amphastar Pharmaceuticals Secures Exclusive Licensing Deal with Anji for Innovative Peptide Therapies in Oncology and Ophthalmology

Reuters
·
Aug 12

Stock Track | Amphastar Pharmaceuticals Soars 9.26% on FDA Approval for Generic Iron Sucrose Injection

Stock Track
·
Aug 11

Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection

Stock Track
·
Aug 11

Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection

Stock Track
·
Aug 11

Amphastar Pharmaceuticals Inc -Announces FDA Approval for Iron Sucrose Injection, Usp

THOMSON REUTERS
·
Aug 11

Amphastar Pharmaceuticals Secures FDA Approval for Generic Iron Sucrose Injection for Treating Iron Deficiency Anemia

Reuters
·
Aug 11

Stock Track | Amphastar Pharmaceuticals Soars 11.79% as Q2 Earnings Surpass Expectations

Stock Track
·
Aug 08

Stock Track | Amphastar Pharmaceuticals Soars 5.41% on Earnings Beat Despite Revenue Dip

Stock Track
·
Aug 08

Cautious Hold Rating on Amphastar Pharmaceuticals Amid Uncertain Product Approvals and Flat Revenue Growth

TIPRANKS
·
Aug 08

Amphastar Pharmaceuticals Q2 2025 Earnings Call Summary and Q&A Highlights: Baqsimi Drives Growth Amid Competitive Pressures

Earnings Call
·
Aug 08

Amphastar (AMPH) Q2 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Aug 08

Stock Track | Amphastar Pharmaceuticals Soars 6.15% After-Hours on Q2 Earnings Beat and Expansion Plans

Stock Track
·
Aug 08